Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on April 17, 2024, reporting events occurring on April 11, 2024. The filing discloses the execution of a new Consulting Agreement with Jay Pepose, M.D., a member of the Company's board of directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
- Monthly Consulting Fee: $39,583.00
- Restricted Stock Units (RSUs): 32,000 shares
- Stock Options: 48,000 shares
- Option Exercise Price: $1.79 per share (based on closing price on April 11, 2024)
Material Changes
The primary material change reported is the appointment of Dr. Pepose as a consultant effective April 11, 2024. This agreement introduces new fixed and equity-based compensation obligations for the Company. The agreement is set to terminate on April 11, 2025, unless mutually extended.
Outlook, Risks, and Unusual Items
Management Commentary and Vesting Schedule:
- RSU Vesting: The 32,000 RSUs will vest in full on April 11, 2025, contingent upon Dr. Pepose's continued service.
- Option Vesting: The 48,000 stock options will vest in 12 equal monthly installments beginning May 11, 2024, subject to continued service.
Risks and Contingencies: The filing notes that the summary of the agreement is qualified by reference to the full text filed as Exhibit 10.1. The compensation is contingent on the consultant's continued service through the specified vesting periods.
Investor Verification Checklist
- Verify the total potential equity dilution from the 32,000 RSUs and 48,000 options granted.
- Review the full text of the Consulting Agreement (Exhibit 10.1) for termination clauses and additional compensation terms not summarized in the 8-K.
- Confirm the impact of the $39,583 monthly fee on the Company's current cash burn rate.
- Check for any related party transaction disclosures regarding Dr. Pepose's dual role as a director and consultant.